Supplementary material 7.
blaTEM | blaSHV | blaCTX-M group I | blaCTX-M group II | blaCTX-M group III | blaCTX-M group IV | |
---|---|---|---|---|---|---|
Isolates from Libyan patients (n=13) | 10a (76.9%) | 6d (46.2%) | 10 (76.9%) | 1 (7.7%) | ||
Isolates from the environment of Libyan patients at the Bundeswehr Hospital of Hamburg (n=5) | 5b (100%) | 4e (80%) | 5 (100%) | |||
Isolates from Syrian patients (n=29) | 15c (51,7%) | 5f (17.2%) | 26 (89.7%) | 1 (3.4%) |
aDistribution of sequences: blaTEM-1 without exception.
bDistribution of sequences: blaTEM-1 without exception.
cDistribution of sequences: blaTEM-1 in 14 instances, not resolved due to different types with identical matching in 1 instance.
dDistribution of sequences: blaSHV-12, blaSHV-1/blaSHV-28 (no further sequence discrimination possible), and blaSHV-33 in one instance each, insufficient discriminatory power in additional 3 instances.
eDistribution of sequences: blaSHV-1/blaSHV-1a (no further sequence discrimination possible), blaSHV-11, and blaSHV-33 in one instance each, insufficient discriminatory power in another instance
fDistribution of sequences: blaSHV-1 in two instances, blaSHV-12/blaSHV-5 (no further sequence discrimination possible) and blaSHV-121/blaSHV-136 (no further sequence discrimination possible) in one instance each, insufficient discriminatory power in another instance.